Please ensure Javascript is enabled for purposes of website accessibility

The Top Stocks on the Dow This Week

By Travis Hoium – Feb 8, 2014 at 1:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Despite a huge slump early in the week, the Dow Jones Industrial Average ended higher and Disney, DuPont, and Pfizer led the way.

It was a wild week on Wall Street, but by the end, the Dow Jones Industrial Average (^DJI 0.45%) had risen 0.61%. There's been fear over an emerging-markets collapse, Federal Reserve tapering, and employment, but at the end of the day it's strong earnings that have kept investors bidding stocks higher. It's another lesson that the daily noise of the market can often distract us from the long-term goal of picking companies that grow their value year after year.

Speaking of consistent growth, Disney (DIS -0.01%) reported another stellar quarter this week, and the stock was up 4.2%. Revenue was up 9% to $12.3 billion, and net income jumped 33% to $1.8 billion on the back of box-office hits Thor: The Dark World and Frozen, which is still near the top of the box office more than two months after being released. Lower content costs at media networks, which is Disney's largest business, helped by increasing operating income 20% in the quarter. In short, Disney is hitting on all cylinders from the box office to theme parks, and that's why it had another great week.  

DuPont (DD) was up 4% this week without much news outside of signing a deal that will allow farmers to access weather and commodity market information from mobile devices. I think the bigger trend here is that investors are looking for value and safe investments with turmoil in early 2014, and DuPont provides that, with a 12 P/E ratio and a dividend yield of 3%.  

Pfizer (PFE 0.74%) rounds out the top three this week with a 3.5% gain after getting good news on a new drug trial. The drug, called palbociclib, significantly delayed progression of symptoms in a breast cancer trial, meeting the trial's primary goal. Analysts think this could be a $5 billion drug for the company and is at the forefront of new cancer treatments being tested today. After years of worrying about drugs coming off patent, investors are welcoming the news that a growth product may be on the way.  

Travis Hoium manages an account that owns shares of DuPont. The Motley Fool recommends and owns shares of Walt Disney. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dow Jones Industrial Average (Price Return) Stock Quote
Dow Jones Industrial Average (Price Return)
^DJI
$34,347.03 (0.45%) $152.97
Walt Disney Stock Quote
Walt Disney
DIS
$98.87 (-0.01%) $0.01
Pfizer Stock Quote
Pfizer
PFE
$49.21 (0.74%) $0.36
DuPont Stock Quote
DuPont
DD

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.